Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 12, 2026, details a material definitive agreement entered into by Bioaffinity Technologies, Inc. (the "Company"). The Company, incorporated in Delaware and trading on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Warrants), executed a private placement transaction that closed on August 14, 2026.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Pre-Funded Warrants, Series A Warrants, and Series B Warrants.
- Securities Issued:
- 8,462,027 Pre-Funded Warrants at $0.4657 per warrant.
- 8,462,027 Series A Warrants (exercise price $0.4727).
- 8,462,027 Series B Warrants (exercise price $0.4727).
- 253,861 Placement Agent Warrants issued to WallachBeth Capital LLC designees.
- Net Proceeds: Approximately $3.6 million after deducting placement agent fees, expenses, and estimated offering costs.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent Fees: 7.5% cash fee of aggregate gross proceeds plus reimbursement of certain expenses and legal fees.
Material Changes and Terms
The filing reports the entry into a Securities Purchase Agreement and a Registration Rights Agreement. Key terms include:
- Exercise Restrictions: Warrants are exercisable following stockholder approval. Holders cannot exercise if it results in ownership exceeding 4.99% of outstanding Common Stock, though this can be increased to 9.99% with 61 days' notice. Pre-Funded Warrants are immediately exercisable at $0.007 per share, subject to a 9.99% ownership limit.
- Expiration: Warrants expire five years after issuance.
- Registration Rights: The Company agreed to file a registration statement within 15 days and have it declared effective within 45 days (or 75 days in the event of a full SEC review).
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to fund working capital and general corporate operations. The filing notes that the issuance of securities relied on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D. No specific financial guidance, revenue projections, or risk factors beyond standard transaction terms were disclosed in this specific filing.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $3.6 million.
- Confirm the status of the registration statement filing and its effectiveness date as required by the Registration Rights Agreement.
- Monitor the Company's announcement regarding the stockholder approval required to exercise the Series A and Series B Warrants.
- Review the impact of the 8,462,027 Pre-Funded Warrants on immediate share count and potential dilution upon exercise.
- Check for any subsequent filings regarding the 4.99% or 9.99% beneficial ownership limits and any notices of increase filed by the Purchaser.